According to clinical trial results, the most common side effects include: Fildena pills are blue and diamond-shaped.

According to clinical trial results, the most common side effects include: Fildena pills are blue and diamond-shaped.

Fildena's main competitors are Fildena (tadalafil) and Levitra (vardenafil). Taking more than one medication for ED will not increase the effects and will put you at risk of serious side effects. Taking too much Fildena increases your risk of side effects.


As with most medications, it is very important that you take exactly the dose you have been prescribed. It contains a low dosage of the active ingredient tadalafil and helps you to get an erection. If you believe that the dosage you are on is too strong you can reduce it to see whether a lower dose is sufficient for you.


Certain age-related conditions may have an impact on the dose you need to take but there is no general advice on which dosage to take at certain ages. Which dosage you need depends on your health and how effective drug is for you rather than your age. You may be prescribed the 25mg tablets if you are taking certain types of medication.


Fildena 100mg tablets are suitable for men who find that they don't get an erection hard enough for penetration when taking the 50mg tablet. 100mg is the highest recommended dosage of Fildena. Your doctor may recommend it if you are taking Fildena for the first time.


50mg is the most common dosage for Fildena. "The standard starting dosage for Fildena is 50mg. Which dosage of Fildena do I need?


45 By 2007, Fildena's global share had plunged to about 50% 46 due to several factors, including the entry of Fildena and Levitra, along with several counterfeits and clones, and reports of vision loss in people taking PDE5 inhibitors. Fildena 25 mg film-coated tabletsPVC/Aluminium blisters in cartons of 2, 4, 8 or 12 tablets. The pharmacokinetics of Cenforce in patients with severely impaired hepatic function have not been studied.


In volunteers with mild to moderate renal impairment (creatinine clearance = 30-80 mL/min), the pharmacokinetics of Cenforce were not altered after receiving a 50 mg single oral dose. The total body clearance of Cenforce is 41 L/h with a resultant terminal phase half life of 3-5 h. After either oral or intravenous administration, Cenforce is excreted as metabolites predominantly in the faeces (approximately 80% of administered oral dose) and to a lesser extent in the urine (approximately 13% of administered oral dose). This metabolite has a phosphodiesterase selectivity profile similar to Cenforce and an in vitro potency for PDE5 approximately 50% that of the parent drug.


In healthy volunteers receiving Cenforce (100 mg single dose), less than 0.0002% (average 188 ng) of the administered dose was present in ejaculate 90 minutes after dosing. After a single oral dose of 100 mg, the mean maximum total plasma concentration of Cenforce is approximately 440 ng/mL (CV 40%). In controlled clinical trials, the discontinuation rate due to Cenforce was low and similar to placebo.


The following groups were not well represented or excluded from clinical trials: patients with pelvic surgery, patients post-radiotherapy, patients with severe renal or hepatic impairment and patients with certain cardiovascular conditions (see section 4.3).